NIVF logo

NewGenIvf Group Limited (NIVF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $2.05, NewGenIvf Group Limited (NIVF) es una empresa del sector Healthcare valorada en 2M. Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 2 mar 2026
Puntuación de IA de 43/100 Objetivo $900.00 (+43802.4%) MCap 2M Vol 41K

NewGenIvf Group Limited (NIVF) Resumen de Asistencia Médica y Tuberías

NewGenIvf Group Ltd. pioneers fertility solutions in Thailand, offering comprehensive assisted reproductive services with a focus on in-vitro fertilization, egg donation, and surrogacy, capitalizing on a high profit margin of 653.9% and a strategic position in the growing medical tourism sector.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 2 mar 2026

Tesis de Inversión

NewGenIvf Group Ltd. presents a notable research candidate due to its strategic positioning in the growing assisted reproductive services market in Thailand. The company's high profit margin of 653.9% indicates efficient operations and strong pricing power. As of 2026-03-02, the company's focus on in-vitro fertilization, egg donation, and surrogacy caters to a rising demand for fertility treatments, both locally and internationally. The key value driver lies in NewGenIVF's ability to attract medical tourists seeking cost-effective and high-quality fertility solutions. The company's commitment to personalized care and advanced medical techniques enhances its competitive advantage. Continued expansion of service offerings and strategic marketing initiatives can further drive revenue growth. Investors should monitor the company's ability to maintain its high profit margins and navigate regulatory landscapes to fully realize the investment potential.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Profit Margin of 653.9% demonstrates strong operational efficiency and pricing power.
  • Focus on in-vitro fertilization (IVF), egg donation, and surrogacy services aligns with growing demand for assisted reproductive technologies.
  • Strategic location in Bangkok, Thailand, positions the company to capitalize on the expanding medical tourism sector.
  • P/E ratio of 0.01 suggests the company is undervalued relative to its earnings.
  • Gross Margin of 18.7% indicates the profitability of core services.

Competidores y Pares

Fortalezas

  • High profit margin of 653.9%.
  • Strategic location in Thailand's medical tourism hub.
  • Comprehensive service offerings including IVF, egg donation, and surrogacy.
  • Established reputation for personalized care.

Debilidades

  • Limited geographic diversification, primarily focused on Thailand.
  • Relatively small employee base of 76, potentially limiting scalability.
  • Dependence on medical tourism trends and economic conditions.
  • No dividend yield, which may deter some investors.

Catalizadores

  • Upcoming: Potential partnerships with international healthcare providers to expand patient reach.
  • Ongoing: Increasing demand for fertility treatments in Thailand and Southeast Asia.
  • Ongoing: Continued advancements in reproductive technologies improving treatment success rates.

Riesgos

  • Potential: Regulatory changes impacting the legality or cost of certain fertility treatments.
  • Potential: Economic downturns reducing medical tourism and patient affordability.
  • Ongoing: Intense competition from other fertility clinics and healthcare providers.
  • Ongoing: Ethical concerns and negative publicity surrounding assisted reproductive technologies.

Oportunidades de crecimiento

  • Expansion into new geographic markets: NewGenIVF can explore opportunities to expand its services to other regions with high demand for fertility treatments, such as Southeast Asia and the Middle East. This expansion could involve establishing new clinics or partnering with existing healthcare providers. The market size for fertility services in these regions is estimated to grow significantly over the next five years, presenting a substantial growth opportunity for NewGenIVF.
  • Development of specialized treatment packages: NewGenIVF can create specialized treatment packages tailored to specific patient needs and preferences. These packages could include comprehensive fertility assessments, genetic testing, and personalized treatment plans. By offering customized solutions, NewGenIVF can attract a wider range of clients and increase revenue per patient. The timeline for developing and launching these packages is estimated to be within the next year.
  • Strategic partnerships with international healthcare providers: NewGenIVF can form strategic partnerships with international healthcare providers to expand its reach and attract more international patients. These partnerships could involve referral agreements, joint marketing initiatives, and collaborative research projects. By collaborating with established healthcare providers, NewGenIVF can enhance its credibility and access new markets. The timeline for establishing these partnerships is estimated to be within the next two years.
  • Investment in advanced technologies: NewGenIVF can invest in advanced reproductive technologies, such as preimplantation genetic testing (PGT) and time-lapse embryo imaging, to improve treatment outcomes and attract more patients. These technologies can enhance the accuracy and efficiency of fertility treatments, leading to higher success rates and increased patient satisfaction. The timeline for implementing these technologies is estimated to be within the next three years.
  • Enhancement of marketing and branding efforts: NewGenIVF can enhance its marketing and branding efforts to increase awareness of its services and attract more clients. This could involve developing a comprehensive marketing strategy, creating engaging content, and utilizing social media platforms to reach potential patients. By strengthening its brand presence, NewGenIVF can differentiate itself from competitors and establish a stronger market position. The timeline for implementing these marketing initiatives is estimated to be ongoing.

Oportunidades

  • Expansion into new geographic markets in Southeast Asia and the Middle East.
  • Development of specialized treatment packages tailored to specific patient needs.
  • Strategic partnerships with international healthcare providers.
  • Investment in advanced reproductive technologies to improve treatment outcomes.

Amenazas

  • Intense competition from other fertility clinics and healthcare providers.
  • Regulatory changes and ethical concerns related to assisted reproductive technologies.
  • Economic downturns impacting medical tourism and patient affordability.
  • Potential for negative publicity or reputational damage.

Ventajas competitivas

  • Established reputation and expertise in assisted reproductive services.
  • Strategic location in Thailand's medical tourism hub.
  • Focus on personalized care and patient satisfaction.
  • Comprehensive service offerings encompassing IVF, egg donation, and surrogacy.

Acerca de NIVF

NewGenIvf Group Ltd., headquartered in Bangkok, Thailand, operates as a specialized assisted reproductive services provider. The company was founded with the mission of helping individuals and couples realize their dreams of starting or expanding their families. NewGenIVF focuses primarily on providing fertility treatments, including in-vitro fertilization (IVF), egg donation, and surrogacy services. Their comprehensive service offerings also encompass ancillary caring services, ensuring a holistic and supportive experience for their clients. Since its inception, NewGenIVF has strategically positioned itself within the burgeoning medical tourism sector of Thailand, catering to both local and international clients seeking advanced reproductive technologies. The company's core business revolves around delivering personalized fertility solutions, leveraging advanced medical techniques and a dedicated team of specialists. NewGenIVF's commitment to quality and patient care has enabled it to establish a strong reputation within the assisted reproductive services market. NewGenIVF's geographic focus remains primarily in Thailand, a hub for medical tourism, allowing the company to tap into a diverse client base. The company continues to refine its service offerings and expand its capabilities to meet the evolving needs of the fertility treatment landscape.

Qué hacen

  • Provides in-vitro fertilization (IVF) treatment services.
  • Offers egg donation services to individuals and couples.
  • Facilitates surrogacy arrangements for those seeking alternative family-building options.
  • Delivers ancillary caring services to support patients throughout their fertility journey.
  • Caters to both local and international clients seeking fertility treatments.
  • Utilizes advanced medical techniques and technologies in reproductive medicine.
  • Offers personalized fertility solutions tailored to individual needs.

Modelo de Negocio

  • Generates revenue through fees for IVF treatments, egg donation, and surrogacy services.
  • Attracts clients through marketing efforts and partnerships with healthcare providers.
  • Provides comprehensive care packages that include medical procedures and support services.
  • Operates clinics and facilities in Thailand to serve local and international patients.

Contexto de la Industria

NewGenIvf Group Ltd. operates within the assisted reproductive technology (ART) industry, a segment experiencing steady growth due to increasing infertility rates and advancements in medical treatments. The global fertility services market is projected to reach billions of dollars by 2030, driven by factors such as delayed pregnancies, lifestyle changes, and rising awareness of ART options. Competitors like IVF and CCM offer similar services, but NewGenIVF differentiates itself through its focus on personalized care and strategic location in Thailand's medical tourism hub. The industry is also subject to regulatory oversight and ethical considerations, impacting operational practices and market access.

Clientes Clave

  • Individuals and couples struggling with infertility.
  • Medical tourists seeking cost-effective fertility treatments.
  • Individuals seeking egg donation or surrogacy services.
  • Patients requiring advanced reproductive technologies.
Confianza de la IA: 75% Actualizado: 2 mar 2026

Finanzas

Gráfico e información

Precio de la acción de NewGenIvf Group Limited (NIVF): $2.05 (+0.04, +1.99%)

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para NIVF.

Objetivos de Precios

Objetivo de consenso: $900.00

MoonshotScore

43/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de NIVF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Lo Que los Inversores Preguntan Sobre NewGenIvf Group Limited (NIVF)

¿Cuáles son los factores clave para evaluar NIVF?

NewGenIvf Group Limited (NIVF) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. La acción cotiza a un P/E de 0.1x, por debajo del promedio del S&P 500 (~20-25x), potencialmente señalando valor. Los analistas apuntan a $900.00 (+43802% desde $2.05). Fortaleza clave: High profit margin of 653.9%.. Riesgo principal a monitorear: Potential: Regulatory changes impacting the legality or cost of certain fertility treatments.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de NIVF?

NIVF actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de NIVF?

Los precios de NIVF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre NIVF?

Los analistas han establecido un precio objetivo de consenso de $900.00 para NIVF, representando un potencial alcista del 43802% desde el precio actual de $2.05. La cobertura incluye calificaciones de compra, mantener y venta, estimaciones de ganancias y recientes mejoras o rebajas. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en NIVF?

Las categorías de riesgo para NIVF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory changes impacting the legality or cost of certain fertility treatments.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de NIVF?

NewGenIvf Group Limited (NIVF) tiene una relación P/E de 0.1, que está por debajo del promedio del mercado, lo que puede sugerir valor relativo. La relación P/E compara el precio de la acción con sus ganancias por acción. Compare con el promedio del S&P 500 (~20-25x) para contexto. Esto no es asesoramiento financiero.

¿Está NIVF sobrevalorada o infravalorada?

Determinar si NewGenIvf Group Limited (NIVF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Su relación P/E es 0.1. Objetivo de analistas $900.00 (+43802% desde el precio actual). Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de NIVF?

NewGenIvf Group Limited (NIVF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information is based on available data and may not reflect all relevant factors.
  • Micro-cap stocks are inherently more volatile and speculative.
Fuentes de datos

Popular Stocks